TradeTrade
Jump to any asset 849 assets, updated daily

As of September 27, 2026, Legend Biotech Corporation (LEGN) trades at $19.11. CleaRank Financial AI rates it Hold with a fair value of $19.11, in line with the current price. Wall Street's consensus target is $48.50 across 14 analysts. RSI at 33 is in neutral territory, and the price is below its 50-day average of $20.26.

Legend Biotech Corporation (LEGN)

Legend Biotech Corporation NASDAQ

$19.11 0.0500 (0.26%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
Hold
55 / 100
Legend Biotech Corporation (LEGN) is currently trading at $19.11, below its 50-day and 200-day moving averages ($20.26 and $22.50), indicating a bearish technical trend. The company has demonstrated impressive revenue growth of 51.9%, significantly outpacing the sector median of 8.1%, and Wall Street analysts have a strong buy consensus with a median price target of $48.5, suggesting substantial upside potential. However, the company is currently loss-making, with a negative EPS of -0.50 and a net profit margin of -7.20%. Insiders have been net sellers, with total sales of $331.5K, signaling moderate caution. While forward revenue estimates are strong, the current price action and insider sentiment warrant a cautious approach.

LEGN Price Analysis

Market Metrics

Open
$19.49
Day Range
$18.85 to $19.69
Prev Close
$19.06
Volume
1.43M
52-Week Range
$16.24 to $37.50
Market Cap
$3.72B

Peer Benchmarking

Valuation vs Sector (Healthcare)

Performance vs XLV

Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, LEGN trades at 2.92x, -21% versus the sector average of 3.70x.

LEGN Financial Performance

Revenue vs. Earnings

Annual

Quarterly

LEGN Analysis

Company's Health 3/5
AI Technical Analysis Hold
Legend Biotech Corporation's stock is currently trading below its 50-day and 200-day moving averages ($20.26 and $22.50), at $20.26 and $22.50 respectively, indicating a bearish trend. The Relative Strength Index (RSI) at 32.81 is in bearish territory, suggesting weakening momentum. Key support levels are not clearly defined given the current trend, while resistance may be found near the 50-day SMA. Volume has been below average recently, with the latest volume at 1.43 million compared to an average of 2.59 million, suggesting a lack of strong conviction from buyers. The chart structure implies further downside risk in the near term.
ProTips
  • Legend Biotech Corporation's stock is trading below key moving averages, suggesting a potential for further downside before a significant recovery. Consider waiting for a confirmed technical breakout.
  • Despite current losses, strong revenue growth and positive forward EPS estimates suggest a potential turnaround. Monitor upcoming earnings reports closely for signs of improving profitability.
  • Insider selling, though moderate, warrants attention. While not a definitive sell signal, it suggests a degree of caution among management regarding near-term stock performance.
Key Catalysts
Bullish Strong Revenue Growth Exceeds Sector Median

Legend Biotech Corporation's revenue growth of 51.9% significantly outpaces the Healthcare sector median of 8.1%, indicating strong market adoption and expansion potential.

Source: Company Data
Bullish High Wall Street Median Price Target

The median analyst price target for LEGN is $48.5, representing a potential upside of 153.8% from the current price, driven by strong future growth estimates.

Source: Wall Street Summary
Bullish Positive Forward EPS Estimates

Analysts project a significant turnaround in profitability, with next year's EPS estimated at $0.6831, a substantial increase from the current negative EPS.

Source: Wall Street Summary
Bearish Bearish Technical Momentum

The stock is trading below its 50-day and 200-day moving averages ($20.26 and $22.50), and the RSI is in bearish territory, indicating a negative short-term trend.

Source: Technical Analysis
Bearish Moderate Insider Selling Signal

Insiders have been net sellers, with total sales of $331.5K, suggesting a degree of caution or profit-taking among management.

Source: Insider Summary
Market Outlook
Legend Biotech Corporation's outlook is cautiously optimistic, driven by strong projected revenue growth and a high Wall Street median price target of $48.5, implying over 150% upside. The company is expected to transition to profitability, with next year's EPS estimate at $0.6831 and a projected 106% growth rate. However, the current bearish technical trend and insider selling present near-term headwinds. A significant catalyst would be a sustained move above the 50-day and 200-day SMAs, coupled with positive earnings surprises and continued strong revenue expansion, to validate the optimistic analyst targets and shift the sentiment.

Key Statistics

Market Cap 3.72B
P/E Ratio N/A (Negative EPS)
EPS (TTM) -0.5000
Dividend Yield 0.00%
52 Week High 37.50
52 Week Low 16.24
Legend Biotech Corporation's valuation appears stretched relative to its current profitability, with a negative P/E ratio due to its -0.50 EPS and a price-to-sales ratio of 2.92, which is below the sector median of 3.7. The company's return on equity is negative at -8.08%, contrasting with the sector median of 6.9%. Despite these profitability concerns, the company exhibits strong revenue growth at 51.9%, significantly exceeding the sector average of 8.1%. Its debt-to-equity ratio of 0.23 is healthy and below the sector median. The forward revenue growth estimates are also very strong, suggesting significant future expansion potential.

Earnings & Growth Analysis

Legend Biotech Corporation's most recent reported EPS was -0.50, which is a loss, and the company's profit margin is -7.20%. While specific quarterly earnings beats or misses are not detailed, the overall trend indicates ongoing losses despite substantial revenue growth. Forward EPS estimates for the next year are positive at $0.6831, suggesting an anticipated turnaround in profitability.

Key Risks

The primary risks for Legend Biotech Corporation include its current unprofitability, evidenced by negative EPS and net profit margin, which could pressure its valuation. Insiders have been net sellers, indicating a degree of caution despite strong revenue growth. Also, the stock is trading below key technical indicators, suggesting potential for further downside momentum.

Technical Indicators i

RSI (14) 32.81
MACD -0.72
SMA 50 20.26
SMA 200 22.50
Technical Rating Bearish
RSI
Bearish
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $20.26, 200-day: $22.50), price is trading below the 50-day SMA.

Market Correlations

How this stock moves relative to other assets

Based on 1 year of daily price data. Correlations may vary over different time periods.

S&P 500 (SPY) +0.15
Weak correlation
Nasdaq 100 (QQQ) +0.14
Weak correlation
Bitcoin (BTC) -0.03
Weak correlation
Gold (XAU) +0.09
Weak correlation
Check Custom Correlation

How does any other asset move with LEGN? One year of daily closes, Pearson correlation.

Try

LEGN Trade Plans

Specific entry, exit, and risk management levels

Select Your Trade Bias
Risk Tolerance
Conservative 2% Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →

Entry Strategies pick an entry style

Conservative
$18.92
Slight discount to current
Wait for small dip
Aggressive
$19.11
At current price
Enter now if confident

Risk Management

STOP LOSS
$17.59
MAX LOSS
-7.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (32.8) and current market volatility

Profit Targets (Based on Conservative Entry)

TARGET 1
$19.49
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$19.86
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$20.43
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
High-Volatility Risk Disclaimer
LEGN is classified as a high-volatility asset (Daily Vol: 3.25%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 27, 2026.

Growth of $10,000

A $10,000 investment in LEGN in June 2020 would be worth about $5,165 today, compared with about $24,155 for the same investment in the S&P 500 benchmark.

Compare with Another Ticker

Monte Carlo Projection (10yr)

CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in LEGN today could grow to about $7,555 by 2036 in the base case, with a bull case near $57,315 and a bear case around $996. Projections are statistical simulations, not guarantees.

LEGN Stock Price Prediction: 2030

CleaRank's simulation projects a price near $17.08 for LEGN by 2030 in the base case, from $19.11 today (0.9x over 4 years). The downside path ends near $4.74. These are outcomes of a Monte Carlo simulation run on LEGN's historical return distribution, not price targets, and they assume no dividends are reinvested.

LEGN simulated price paths by year
Year Downside (10th pct) Base case Upside (90th pct)
2027 $9.79 $18.58 $35.27
2028 $7.30 $18.07 $44.72
2029 $5.79 $17.57 $53.30
2030 $4.74 $17.08 $61.54
2031 $3.96 $16.61 $69.61
2032 $3.36 $16.15 $77.60
2033 $2.88 $15.70 $85.57
2034 $2.49 $15.27 $93.54
2035 $2.17 $14.85 $102
2036 $1.90 $14.44 $110

Method: 10,000 simulated price paths using LEGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.

People Also Watch

LEGN Insider Trading Analysis

Source: SEC Form 4
▲ Bought
None
No open-market buys
▼ Sold
$331.5K
2 Transactions
● Insiders
3
Active Traders
$ Avg Transaction
$165.8K
Moderate size
Recent insider transactions in LEGN
Date Insider Type Shares Value
Jun 30, 2026
CASEY PATRICK JOHN PH.D.
Director
Sell 6.0K $173.3K
Jun 25, 2026
HUANG YING
Chief Executive Officer
Sell 5.6K $158.2K
Aug 14, 2026
BASH ALAN
Chief Executive Officer
Grant 4.9K -
Jun 30, 2026
HUANG YING
Chief Executive Officer
Grant 3.4K -

Frequently Asked Questions

What is Legend Biotech Corporation's stock price forecast for 2030?
Legend Biotech Corporation's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $17.08, a downside scenario of $4.74, and an upside scenario of $61.54. These figures represent statistical outcomes and are not guarantees.
Is Legend Biotech Corporation stock a buy right now?
Legend Biotech Corporation is currently rated a 'Hold' with a consensus score of 55. While Wall Street has a strong buy consensus and a median price target of $48.5, the stock is trading below key moving averages and insiders have been net sellers.
What is Legend Biotech Corporation's current technical outlook?
The technical outlook for Legend Biotech Corporation is bearish, with the stock trading below its 50-day and 200-day moving averages ($20.26 and $22.50) and exhibiting bearish RSI momentum. Volume has also been below average, indicating a lack of buying conviction.
How does Legend Biotech Corporation compare to its sector averages?
Legend Biotech Corporation significantly outperforms its sector in revenue growth (51.9% vs. 8.1% median) but lags in profitability metrics like ROE (-8.08% vs. 6.9% median). Its P/E is negative, while the sector median is 31.9.
What are the key risks facing Legend Biotech Corporation?
Key risks include the company's current unprofitability, insider net selling activity, and a bearish technical trend. These factors counterbalance the strong revenue growth and optimistic analyst price targets.
What is the Wall Street consensus on Legend Biotech Corporation?
Wall Street analysts maintain a 'Strong Buy' consensus for Legend Biotech Corporation, with 5 strong buys and 4 buys out of 14 analysts. The median price target is $48.5, indicating a significant upside potential from the current price.
What is Legend Biotech Corporation's profitability status?
Legend Biotech Corporation is currently loss-making, reporting a negative EPS of -0.50 and a net profit margin of -7.20%. However, forward EPS estimates for next year are positive, suggesting an anticipated improvement in profitability.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis, trade plans, and AI-generated signals presented for LEGN are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All trade setups and performance metrics shown are hypothetical, hindsight-based, and simulated. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by 15 minutes or more. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on September 27, 2026.

Disclaimer:

Engaging in financial markets carries significant risk of total capital loss. Markets are volatile, unpredictable, and past success does not guarantee future results. Never invest funds you cannot afford to lose. CleaRank does not offer financial, investment, or advisory services. We provide no recommendations, endorsements, or guarantees regarding market outcomes. You alone are responsible for your decisions.

Advertiser Disclosure:

At CleaRank, clarity and transparency are more than ideals, they are the core of our operations. CleaRank is a paid SaaS platform: the Pro and Ultra workbench plans are paid subscriptions, while everything else on this site, including our trading calculators, tools and market news, is free to use. In the spirit of full disclosure: some of our free editorial content contains partner links, and we may earn affiliate commissions from them. This never affects what you pay. Please keep in mind that your confidence in our platform is what matters to us most and we are devoted to earning your trust every day through consistent transparency. CleaRank's Editorial team works independently from partner relationships and financial incentives. All material and information made available by CleaRank stem from our unique technology and methodology which are created to prioritize your needs as a trader and deliver actionable insights to help you make clearer decisions.